A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Novartis
Regeneron Pharmaceuticals
Genmab
Dana-Farber Cancer Institute
Therapeutic Advances in Childhood Leukemia Consortium
University of Leeds
Oncotherapeutics
Oncotherapeutics
Memorial Sloan Kettering Cancer Center
Sun Yat-sen University
Northwestern University
Fondazione EMN Italy Onlus
Fred Hutchinson Cancer Center